FAST BioMedical is a privately held company based in Indianapolis developing late clinical-stage medical technology with the aim of improving the treatment of heart failure and related diseases. The company’s globally patented technology is designed to be the first to directly measure volume status and kidney function in a clinically actionable way, which has the potential for significant impact on the treatment of patients with heart failure, cardiorenal syndrome, sepsis, and acute kidney injury (AKI). FAST BioMedical has completed four human trials in Europe and the United States.
